LONG BEACH, Calif. — Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity gains vs. aflibercept but did not meet the primary endpoint of the NEW DAY study.
“Although the NEW DAY study did not meet its primary endpoint, it yielded important and clinically meaningful insights,” Michael A. Singer, MD, who presented the results at the American Society of Retina Specialists annual meeting, told Healio.
The multicenter, masked, randomized, active-controlled, parallel-group study enrolled 306 intent-to-treat (ITT)